Sai Parenterals Limited Q4 FY26 earnings call summary

Earnings call of 27 May 2026, summarised by AI from the filing.

Sai Parenterals guides FY27 revenue at ₹750 cr and EBITDA margin at 17%, after Q4 FY26 revenue of ₹198 cr.

Key takeaways

1. Q4 revenue ₹198 cr with EBITDA ₹29 cr (15% margin) and PAT ₹13 cr.
2. FY27 guidance Revenue ₹750 cr and EBITDA margin 17%, with no capex contribution.
3. Capex program ₹440 cr growth capex across India and Australia, completing in FY27.
4. Debt peak Total debt ₹319 cr; peak expected in FY27, decline from FY28.

Original filing on BSE

Sai Parenterals Limited Q1 FY27 results

As filed: Revenue ₹179 cr, EBITDA ₹23.5 cr, PAT ₹7.9 cr, EBITDA margin 13.2%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹179 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹198 cr, EBITDA ₹26.1 cr, PAT ₹13.2 cr, EBITDA margin 13.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹198 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +0.2% in 30 days (Nifty 500: −1.5%).
• Q3 FY26: Revenue ₹96.2 cr, EBITDA −₹3.6 cr, PAT −₹6.7 cr, EBITDA margin -3.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹96.2 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Sai Parenterals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (12 Aug 2026), Results deck (12 Aug 2026)
• Q4 FY26: Earnings call (27 May 2026), Results deck (26 May 2026), Results press release (23 May 2026)